Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...

The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address the growing skills shortage in the UK’s medicines manufacturing ...

Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National Institute for Health and Care Excellence (NICE) has issued guidance recommending Santen’s ...

Study reveals potential new strategy for managing inflammatory bowel disease Celltrion has announced groundbreaking results from a two-year study on dose escalation of subcutaneous infliximab (CT-P13 ...

Innovative Trials has appointed Ian Keith as Finance and Business Services Director Innovative Trials has appointed Ian Keith, who has been supporting the company as a Business Consultant since the ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...

Sanofi has announced the launch of its high-dose egg-based quadrivalent influenza vaccine (QIV-HD) in the UK. This vaccine is designed for people aged 65 and older, as well as clinically at-risk ...

Lundbeck has announced a significant step forward in its Focused Innovator strategy with the acquisition of Longboard Pharmaceuticals. This strategic deal, valued at approximately USD 2.6 billion, ...

The Scottish Medicines Consortium (SMC) has recommended MSD’s KEYTRUDA (pembrolizumab) as a monotherapy for adults with non-small cell lung carcinoma (NSCLC) who are at high risk of recurrence ...

Teclistamab (Tecvayli), a drug manufactured by Johnson & Johnson, has received a positive recommendation from NICE for fourth-line use on the NHS in England and Wales. This new treatment is for ...

Janssen-Cilag therapy becomes the first single tablet combination therapy for PAH in europe The European Commission has approved Yuvanci (macitentan 10 mg and tadalafil 40 mg), a single tablet ...